Can you please expand on how you see RC220 as a platform opportunity? I know I am asking you to speculate, but I do find things a bit too hazy at the moment.
So hazy that I suspect some holders may be hesitant to add to their holdings, even at these so called give-away levels! I certainly am hesitant!
The direction seems uclear (to me anyway). We have a drug that does everything, plus 39 molecules that are either the same as the drug that does everything, or different, perhaps better, or not! We have the funded AML trial that might or might not be done. And the Domm data that might or might not be revealed, if it exists. I do not know if I am coming or going!
Add to the shared silence at OPT and at RAC, and I sure do not know if I am coming or going!
Add to My Watchlist
What is My Watchlist?
